Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 58Leukemia 52Lymphoma 37Myelodysplastic Syndromes 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Lymphoma, Non-Hodgkin 22Hodgkin Disease 22Leukemia, Myeloid, Acute 18Multiple Myeloma 17Myeloproliferative Disorders 14Recurrence 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, T-Cell, Peripheral 10Lymphoma, Follicular 10Congenital Abnormalities 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Hematologic Neoplasms 9Burkitt Lymphoma 9Anemia, Aplastic 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Waldenstrom Macroglobulinemia 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Graft vs Host Disease 7Sezary Syndrome 6Primary Myelofibrosis 6

Interventions

Cyclophosphamide 3thymoglobulin 2luspatercept 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Alemtuzumab × Clear all
NCT01049854 2018-08-21

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

Phase 2 Completed
20 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Metabolism, Inborn Errors, Histiocytosis, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡